HZNP
http://www.sec.gov/Archives/edgar/data/1492426/000119312516537923/d168463d8k.htm
Horizon Pharma is confirming its full-year 2016 net sales guidance of $1.025 to $1.050 billion and full-year 2016 adjusted EBITDA guidance of $505 to $520 million, representing 37 percent and 41 percent growth at the midpoints, respectively.
La compañía confirma guidance para este 2016.
premarket -12% con volumen , unas 172k acciones
"states revenue expectations for 2016 are $1.025B - 1.050B (+37% at midpoint), in line with the consensus view of $1.03B. The company appears to be a bit slippery with its quarterly guidance, however. Instead of presenting its top-line expectations as it does for the year, it provides only percentages. Doing the math for Q1, its guidance range is ~$195M - 210M, below the consensus view of $228M."